Pivotal Therapeutics Exhibiting at the American College of Cardiology's 62nd Annual Scientific Session and EXPO
06 Março 2013 - 2:42PM
OTC Markets
Pivotal Therapeutics Exhibiting at the American College of
Cardiology's 62nd Annual Scientific Session and EXPO
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
Pivotal Therapeutics Exhibiting at the American College of
Cardiology's 62nd Annual Scientific Session and EXPO
PR Newswire
WOODBRIDGE, ON, March 6, 2013
WOODBRIDGE, ON, March 6, 2013 /PRNewswire/ - Pivotal
Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty
pharmaceutical company with a focus on optimizing Omega-3
therapy for cardiovascular disease and overall health, is pleased
to
announce it will exhibiting at the American College of Cardiology's
62nd Annual Scientific Session and EXPO (ACC),
March 9-11, 2013 at the
Moscone Center in San Francisco,
California, Booth # S2544. The ACC is
the largest gathering of cardiovascular products and services, with
the
latest advances and solutions in cardiovascular science and
care.
"With more that 13,000 cardiovascular professionals attending the
ACC,
it is a perfect venue to showcase VASCAZEN® the
only prescription Omega-3 therapy specifically formulated for
the
correction of an Omega-3 deficiency in cardiovascular patients,"
said
Dr. George Jackowski, Chairman and
Chief Scientific Officer. "Pivotal
will have an opportunity to educate attendees on the benefits
patients
see as a result of correcting an Omega-3 deficiency with
VASCAZEN®."
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada
and Boca Raton, Florida,
Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty
pharmaceutical company with a focus on cardiovascular disease
and
overall health. Pivotal Therapeutics' lead product
VASCAZEN® is a prescription only Medical Food
formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease
through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid
(DHA) to
levels associated with reduced risk of cardiovascular
complications.
VASCAZEN® is a prescription only Medical Food
specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular
patients.
VASCAZEN® is a >90% pure Omega-3 with a
proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign
patents.
This unique formulation provides the cornerstone upon which a
family of
cutting edge combination products, with efficacy across a broad
spectrum of cardiac care, will be commercialized.
OMAZENTM is a prescription grade Omega-3
providing >90% total Omega-3 in each
capsule with a unique 6:1 ratio of EPA:DHA.
OMAZENTM is a patented product available for sale
and distribution in Canada.
Disclosure Notice
The information contained in this document is as of March 6, 2013. This
press release contains forward-looking statements. Such
forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to
differ
materially from those projected in such forward-looking
statements.
These statements can be identified by the use of words such as
"will",
"anticipate", "estimate", "expect", "project", "forecast",
"intend",
"plan", "believe", "project", "potential", and similar expressions
with
any discussion of future operating or financial performance or
events.
In particular, factors that could cause actual results to
differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing
on
acceptable terms; growth in costs and expenses; inability to
compete
with others who provide comparable products; risk that the
Company's
products will not gain widespread market acceptance; risks relating
to
the Company's ability to maintain its CSNX listing.
Forward-looking
statements speak only as of the date made and are not guarantees
of
future performance. The Company undertakes no obligation to
publicly
update or revise any forward-looking statements contained in
this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept
responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
Pivotal Therapeutics (CE) (USOTC:PVTTF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Pivotal Therapeutics (CE) (USOTC:PVTTF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024